US20080076134A1 - Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan - Google Patents

Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan Download PDF

Info

Publication number
US20080076134A1
US20080076134A1 US11/903,470 US90347007A US2008076134A1 US 20080076134 A1 US20080076134 A1 US 20080076134A1 US 90347007 A US90347007 A US 90347007A US 2008076134 A1 US2008076134 A1 US 2008076134A1
Authority
US
United States
Prior art keywords
genes
irinotecan
gene
patients
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/903,470
Other languages
English (en)
Inventor
Patrick Muraca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuclea Biomarkers LLC
Original Assignee
Nuclea Biomarkers LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuclea Biomarkers LLC filed Critical Nuclea Biomarkers LLC
Priority to US11/903,470 priority Critical patent/US20080076134A1/en
Assigned to NUCLEA BIOMARKERS, LLC reassignment NUCLEA BIOMARKERS, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MURACA, PATRICK J.
Publication of US20080076134A1 publication Critical patent/US20080076134A1/en
Priority to US12/284,387 priority patent/US7763438B2/en
Priority to US12/487,061 priority patent/US8580926B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
US11/903,470 2006-09-21 2007-09-21 Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan Abandoned US20080076134A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/903,470 US20080076134A1 (en) 2006-09-21 2007-09-21 Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
US12/284,387 US7763438B2 (en) 2006-09-21 2008-09-22 Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
US12/487,061 US8580926B2 (en) 2006-09-21 2009-06-18 Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84629806P 2006-09-21 2006-09-21
US90643807P 2007-03-12 2007-03-12
US11/903,470 US20080076134A1 (en) 2006-09-21 2007-09-21 Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/284,387 Division US7763438B2 (en) 2006-09-21 2008-09-22 Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
US12/487,061 Continuation US8580926B2 (en) 2006-09-21 2009-06-18 Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan

Publications (1)

Publication Number Publication Date
US20080076134A1 true US20080076134A1 (en) 2008-03-27

Family

ID=39512250

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/903,470 Abandoned US20080076134A1 (en) 2006-09-21 2007-09-21 Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
US12/284,387 Expired - Fee Related US7763438B2 (en) 2006-09-21 2008-09-22 Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
US12/487,061 Expired - Fee Related US8580926B2 (en) 2006-09-21 2009-06-18 Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/284,387 Expired - Fee Related US7763438B2 (en) 2006-09-21 2008-09-22 Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
US12/487,061 Expired - Fee Related US8580926B2 (en) 2006-09-21 2009-06-18 Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan

Country Status (5)

Country Link
US (3) US20080076134A1 (da)
EP (1) EP2081950B1 (da)
DK (1) DK2081950T3 (da)
ES (1) ES2405654T3 (da)
WO (1) WO2008073177A2 (da)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126543A1 (en) 2008-04-08 2009-10-15 Nuclea Biomarkers, Llc Biomarker panel for prediction of recurrent colorectal cancer
US20100120080A1 (en) * 2008-11-03 2010-05-13 Quest Diagnostics Investments Incorporated Cancer diagnosis using ki-67
KR20110137305A (ko) * 2009-03-13 2011-12-22 각코우호우징 사이타마이카다이가쿠 이리노테칸의 감수성 판정 방법 및 그 이용
EP2589665A1 (en) * 2010-06-29 2013-05-08 Kurume University Method for predicting therapeutic effect of immunotherapy on cancer patient, and gene set and kit to be used in the method
JP5548693B2 (ja) * 2009-10-30 2014-07-16 学校法人慶應義塾 抗がん剤の感受性判定方法
JP5548694B2 (ja) * 2009-10-30 2014-07-16 学校法人慶應義塾 抗がん剤の感受性の判定方法
EP2881472A1 (en) * 2013-12-09 2015-06-10 Université Pierre et Marie Curie (Paris 6) A method of predicting a response to an anti-tumor treatment
JP2015537208A (ja) * 2012-11-01 2015-12-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 心不全リスクの予測改善のためのバイオマーカー

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
WO2016046640A2 (en) * 2014-09-26 2016-03-31 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
EP3662751B1 (en) * 2015-05-26 2021-10-13 Kaohsiung Medical University Pyrazolo[4,3-c]quinoline derivatives for inhibition of b-glucuronidase
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569755A (en) * 1993-03-05 1996-10-29 The United States Of America As Represented By The Department Of Health And Human Services Colon mucosa gene having down regulated expression in colon adenomas and adenocarcinomas
US5733748A (en) * 1995-06-06 1998-03-31 Human Genome Sciences, Inc. Colon specific genes and proteins
US6337195B1 (en) * 1995-06-06 2002-01-08 Human Genome Sciences, Inc. Colon specific genes and proteins
US6455668B1 (en) * 2000-01-28 2002-09-24 Eos Biotechnology, Inc. Methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US6455251B1 (en) * 1994-09-13 2002-09-24 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
US6468790B1 (en) * 1998-10-15 2002-10-22 Chiron Corporation Metastatic breast and colon cancer regulated genes
US6566502B1 (en) * 2000-01-28 2003-05-20 Eos Biotechnology, Inc. Methods of diagnosing cancer, compositions, and methods of screening for cancer modulators
US6602659B1 (en) * 1996-05-03 2003-08-05 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
US6635748B2 (en) * 1997-12-31 2003-10-21 Chiron Corporation Metastatic breast and colon cancer regulated genes
US6682890B2 (en) * 2000-08-17 2004-01-27 Protein Design Labs, Inc. Methods of diagnosing and determining prognosis of colorectal cancer
US20040146921A1 (en) * 2003-01-24 2004-07-29 Bayer Pharmaceuticals Corporation Expression profiles for colon cancer and methods of use
US6773878B1 (en) * 1999-11-09 2004-08-10 Eos Biotechnology, Inc. Methods of diagnosing of colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US20040157255A1 (en) * 2003-02-06 2004-08-12 David Agus Gene expression markers for response to EGFR inhibitor drugs
US6794501B2 (en) * 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
US20040203034A1 (en) * 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan
US6949339B1 (en) * 1998-05-21 2005-09-27 Diadexus, Inc. Method of diagnosing, monitoring, and staging colon cancer
US20050227266A1 (en) * 2004-02-06 2005-10-13 Ross Douglas T Biomarker:compound correlations in cancer diagnosis and therapy
US20050260646A1 (en) * 2004-04-09 2005-11-24 Genomic Health Inc. Gene expression markers for predicting response to chemotherapy
US20060094068A1 (en) * 2002-06-19 2006-05-04 Bacus Sarah S Predictive markers in cancer therapy
US7056674B2 (en) * 2003-06-24 2006-06-06 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
US7081340B2 (en) * 2002-03-13 2006-07-25 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20060166230A1 (en) * 2004-11-05 2006-07-27 Baker Joffre B Predicting response to chemotherapy using gene expression markers
US20060166231A1 (en) * 2004-11-05 2006-07-27 Joffre Baker Molecular indicators of breast cancer prognosis and prediction of treatment response
US20060246433A1 (en) * 2002-02-27 2006-11-02 Epigenomics Ag Method and nucleic acids for the analysis of a colon cell proliferative disorder
US20070105142A1 (en) * 2005-10-31 2007-05-10 Scott Wilhelm Methods for prognosis and monitoring cancer therapy
US20070190583A1 (en) * 2004-06-04 2007-08-16 Smithkline Beecham Corporation Predicitive biomarkers in cancer therapy
US20070212738A1 (en) * 2005-03-16 2007-09-13 Haley John D Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US20080014579A1 (en) * 2003-02-11 2008-01-17 Affymetrix, Inc. Gene expression profiling in colon cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058102A1 (fr) * 1999-03-31 2000-10-05 Copyer Co., Ltd. Imprimante
US20050009110A1 (en) * 2003-07-08 2005-01-13 Xiao-Jia Chang Methods of producing antibodies for diagnostics and therapeutics
US20070221273A1 (en) * 2006-03-22 2007-09-27 Landers Jerry L Valve for beverage dispenser

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831015A (en) * 1993-03-05 1998-11-03 The United State Of America As Represented By The Department Of Health And Human Services Colon mucosa gene having down-regulated expression in colon adenumas and adenocarcinomas
US6210887B1 (en) * 1993-03-05 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Methods for evaluating colon tissue for expression of the DRA (down regulated in adenoma) gene
US5569755A (en) * 1993-03-05 1996-10-29 The United States Of America As Represented By The Department Of Health And Human Services Colon mucosa gene having down regulated expression in colon adenomas and adenocarcinomas
US6455251B1 (en) * 1994-09-13 2002-09-24 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
US5733748A (en) * 1995-06-06 1998-03-31 Human Genome Sciences, Inc. Colon specific genes and proteins
US6337195B1 (en) * 1995-06-06 2002-01-08 Human Genome Sciences, Inc. Colon specific genes and proteins
US6831152B2 (en) * 1995-06-06 2004-12-14 Human Genome Sciences, Inc. Colon specific genes and proteins
US6602659B1 (en) * 1996-05-03 2003-08-05 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
US6635748B2 (en) * 1997-12-31 2003-10-21 Chiron Corporation Metastatic breast and colon cancer regulated genes
US6949339B1 (en) * 1998-05-21 2005-09-27 Diadexus, Inc. Method of diagnosing, monitoring, and staging colon cancer
US6468790B1 (en) * 1998-10-15 2002-10-22 Chiron Corporation Metastatic breast and colon cancer regulated genes
US6773878B1 (en) * 1999-11-09 2004-08-10 Eos Biotechnology, Inc. Methods of diagnosing of colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US6566502B1 (en) * 2000-01-28 2003-05-20 Eos Biotechnology, Inc. Methods of diagnosing cancer, compositions, and methods of screening for cancer modulators
US6455668B1 (en) * 2000-01-28 2002-09-24 Eos Biotechnology, Inc. Methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US6682890B2 (en) * 2000-08-17 2004-01-27 Protein Design Labs, Inc. Methods of diagnosing and determining prognosis of colorectal cancer
US6794501B2 (en) * 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
US20060246433A1 (en) * 2002-02-27 2006-11-02 Epigenomics Ag Method and nucleic acids for the analysis of a colon cell proliferative disorder
US7081340B2 (en) * 2002-03-13 2006-07-25 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20060094068A1 (en) * 2002-06-19 2006-05-04 Bacus Sarah S Predictive markers in cancer therapy
US20040203034A1 (en) * 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan
US20040146921A1 (en) * 2003-01-24 2004-07-29 Bayer Pharmaceuticals Corporation Expression profiles for colon cancer and methods of use
US20040157255A1 (en) * 2003-02-06 2004-08-12 David Agus Gene expression markers for response to EGFR inhibitor drugs
US20080014579A1 (en) * 2003-02-11 2008-01-17 Affymetrix, Inc. Gene expression profiling in colon cancers
US7056674B2 (en) * 2003-06-24 2006-06-06 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
US20050227266A1 (en) * 2004-02-06 2005-10-13 Ross Douglas T Biomarker:compound correlations in cancer diagnosis and therapy
US20050260646A1 (en) * 2004-04-09 2005-11-24 Genomic Health Inc. Gene expression markers for predicting response to chemotherapy
US20070190583A1 (en) * 2004-06-04 2007-08-16 Smithkline Beecham Corporation Predicitive biomarkers in cancer therapy
US20060166230A1 (en) * 2004-11-05 2006-07-27 Baker Joffre B Predicting response to chemotherapy using gene expression markers
US20060166231A1 (en) * 2004-11-05 2006-07-27 Joffre Baker Molecular indicators of breast cancer prognosis and prediction of treatment response
US20070212738A1 (en) * 2005-03-16 2007-09-13 Haley John D Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US20070105142A1 (en) * 2005-10-31 2007-05-10 Scott Wilhelm Methods for prognosis and monitoring cancer therapy

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126543A1 (en) 2008-04-08 2009-10-15 Nuclea Biomarkers, Llc Biomarker panel for prediction of recurrent colorectal cancer
EP2271775A1 (en) * 2008-04-08 2011-01-12 Nuclea Biomarkers LLC Biomarker panel for prediction of recurrent colorectal cancer
US20110059464A1 (en) * 2008-04-08 2011-03-10 Muraca Patrick J Biomarker Panel For Prediction Of Recurrent Colorectal Cancer
EP2271775A4 (en) * 2008-04-08 2011-09-07 Nuclea Biomarkers Llc BIOMARKERGROUP FOR PREDICTING THE REPRESENTATION OF COLORECTAL CARCINOMA
US20100120080A1 (en) * 2008-11-03 2010-05-13 Quest Diagnostics Investments Incorporated Cancer diagnosis using ki-67
US9107918B2 (en) 2009-03-13 2015-08-18 Kabushiki Kaisha Yakult Honsha Method for determining sensitivity to irinotecan and use thereof
CN102325905A (zh) * 2009-03-13 2012-01-18 学校法人埼玉医科大学 伊立替康的敏感性判断方法及其利用
EP2407556A1 (en) * 2009-03-13 2012-01-18 Saitama Medical University Method for determining sensitivity to irinotecan and use thereof
EP2407556A4 (en) * 2009-03-13 2012-11-28 Univ Saitama Medical METHOD FOR DETERMINING THE SENSITIVITY TO IRINOTECAN AND USE THEREOF
JP5774473B2 (ja) * 2009-03-13 2015-09-09 株式会社ヤクルト本社 イリノテカンの感受性判定方法及びその利用
KR20110137305A (ko) * 2009-03-13 2011-12-22 각코우호우징 사이타마이카다이가쿠 이리노테칸의 감수성 판정 방법 및 그 이용
JP5548694B2 (ja) * 2009-10-30 2014-07-16 学校法人慶應義塾 抗がん剤の感受性の判定方法
JP5548693B2 (ja) * 2009-10-30 2014-07-16 学校法人慶應義塾 抗がん剤の感受性判定方法
EP2589665A4 (en) * 2010-06-29 2013-11-20 Univ Kurume METHOD FOR PREDICTING THE THERAPEUTIC EFFECT OF IMMUNOTHERAPY ON CANCER PATIENT, AND SET OF GENES AND KIT FOR USE IN THE METHOD
EP2589665A1 (en) * 2010-06-29 2013-05-08 Kurume University Method for predicting therapeutic effect of immunotherapy on cancer patient, and gene set and kit to be used in the method
JP2015537208A (ja) * 2012-11-01 2015-12-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 心不全リスクの予測改善のためのバイオマーカー
US11686736B2 (en) 2012-11-01 2023-06-27 Christie Mitchell Ballantyne Biomarkers to improve prediction of heart failure risk
EP2881472A1 (en) * 2013-12-09 2015-06-10 Université Pierre et Marie Curie (Paris 6) A method of predicting a response to an anti-tumor treatment
WO2015086583A1 (en) * 2013-12-09 2015-06-18 Universite Pierre Et Marie Curie (Paris 6) A method of predicting a response to an anti-tumor treatment
US10508310B2 (en) 2013-12-09 2019-12-17 Sorbonne Universite Method of predicting a response to an anti-tumor treatment

Also Published As

Publication number Publication date
ES2405654T3 (es) 2013-05-31
WO2008073177A3 (en) 2008-11-06
US8580926B2 (en) 2013-11-12
DK2081950T3 (da) 2013-06-03
EP2081950A2 (en) 2009-07-29
EP2081950B1 (en) 2013-03-20
US20090047684A1 (en) 2009-02-19
WO2008073177A2 (en) 2008-06-19
US20090298084A1 (en) 2009-12-03
US7763438B2 (en) 2010-07-27
EP2081950A4 (en) 2010-03-17

Similar Documents

Publication Publication Date Title
US7763438B2 (en) Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
US8900820B2 (en) Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors
US8349555B2 (en) Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
JP2022512080A (ja) 次世代分子プロファイリング
WO2009158620A2 (en) Signatures and determinants associated with metastasis methods of use thereof
JP2011525106A (ja) 瀰漫性ｂ大細胞型リンパ腫のマーカーおよびその使用方法
JP2022522948A (ja) ゲノムプロファイリングの類似性
US20150344962A1 (en) Methods for evaluating breast cancer prognosis
US8883419B2 (en) Methods and kits useful for the identification of astrocytoma, it's grades and glioblastoma prognosis
US20110059464A1 (en) Biomarker Panel For Prediction Of Recurrent Colorectal Cancer
EP2550534A1 (en) Prognosis of oesophageal and gastro-oesophageal junctional cancer
KR101346955B1 (ko) 뇌종양의 재발 가능성 및 생존 예후 예측용 조성물 및 이를 포함하는 키트
WO2010003772A1 (en) Method for predicting adverse response to erythropoietin in breast cancer treatment
KR20090025898A (ko) 폐암 환자의 폐암 재발 위험을 예측하기 위한 마커, 키트,마이크로어레이 및 방법
US20150309034A1 (en) Biomarker panel for prediction of recurrent colon cancer
WO2010138843A2 (en) Acute lymphoblastic leukemia (all) biomarkers

Legal Events

Date Code Title Description
AS Assignment

Owner name: NUCLEA BIOMARKERS, LLC, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MURACA, PATRICK J.;REEL/FRAME:019945/0351

Effective date: 20070914

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION